Human seminal alpha-inhibins

• US 4,624,944 A
• Filed: 06/14/1985
• Issued: 11/25/1986
• Est. Priority Date: 06/14/1985
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Chung, David, Hammonds, R. Glenn Jr., Ramasharma, Kristipati, Li, Choh H.
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US06/745,279
• Time in Patent Office: 529 Days
• Field of Search: 260/112.5 R, 514/12, 530/324
• US Class Current: 514/9.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: Y10S 930/11 Gonadotropin; related peptides

Abstract

The present invention discloses novel gonadal peptides with inhibin-like activity. The novel peptides include two gonadal peptides, one consisting of 52 amino acids, the other consisting of 92 amino acids. Both of these peptides were initially isolated from human seminal plasma. Both have now been chemically synthesized. The novel peptides are designated as alpha-inhibin-52 and alpha-inhibin-92. Sequence analyses show that the NH₂ -terminal 31 amino acids of alpha-inhibin-52 are identical to the structure of the 31 amino acid inhibin-like peptide previously reported by Ramasharma, et al. (1984). Sequence analyses also show that the COOH-terminal 52 amino acids of alpha-inhibin-92 are identical to the structure of alpha-inhibin-52. The amino acid sequence of alpha-inhibin-92 is: ##STR1## .

Claims

1. An essentially pure peptide compound having the formula:

##STR5## or a nontoxic salt of said peptide.

3. A fragment (F) of the essentially pure alpha-IB-92 peptide compound of claim 1 wherein said fragment (F) is a fragment composed of less than all the 92 amino acids comprising alpha-IB-92;

wherein said fragment (F) further is a fragment other than the 31 amino acid fragment alpha-IB-31 composed of;

##STR7## and wherein said fragment (F) is biologically active in suppressing lutropin-releasing hormone (LHRH)-induced FSH secretion by the anterior pituitary gland;

or a nontoxic salt of such peptide fragment (F).

4. A pharmaceutical composition for suppressing lutropin-releasing hormone (LHRH)-induced FSH secretion by the anterior pituitary gland comprising a lutropin-releasing hormone (LHRH)-induced FSH-suppressing amount of essentially pure alpha-IB-92, as disclosed in claim 1, or a fragment (F) thereof, as disclosed in claim 3, or nontoxic salts thereof, in combination with a pharmaceutically acceptable carrier.

6. A method for suppressing FSH secretion by the anterior pituitary gland comprising

administering an effective amount of essentially pure alpha-IB-92, as disclosed in claim 1, or a fragment (F) thereof, as disclosed in claim 3, wherein said effective amount is an amount sufficient to suppress lutropin-releasing hormone (LHRH)-induced FSH secretion by the anterior pituitary gland.

2. An essentially pure peptide compound having the formula:

##STR6## or a nontoxic salt of said peptide.

5. A pharmaceutical composition for suppressing lutropin-releasing hormone (LHRH)-induced FSH secretion by the anterior pituitary gland comprising a lutropin-releasing hormone (LHRH)-induced FSH-suppressing effective amount of essentially pure alpha-IB-52, as disclosed in claim 2, or a nontoxic salt thereof, in combination with a pharmaceutically acceptable carrier.

7. A method for suppressing FSH secretion by the anterior pituitary gland comprising

administering an effective amount of essentially pure alpha-IB-52, as disclosed in claim 2, wherein said effective amount is an amount sufficient to suppress lutropin-releasing hormone (LHRH)-induced FSH secretion by the anterior pituitary gland.